These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31243789)

  • 1. Clinical outcomes with unfractionated heparin monitored by anti-factor Xa vs. activated partial Thromboplastin time.
    Coons JC; Iasella CJ; Thornberg M; Fitzmaurice MG; Goehring K; Jablonski L; Leader D; Meyer A; Seo H; Benedict NJ; Smith RE
    Am J Hematol; 2019 Sep; 94(9):1015-1019. PubMed ID: 31243789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
    Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
    Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
    Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP
    Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
    Belk KW; Laposata M; Craver C
    J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
    Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
    Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
    Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
    Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of anti-XA-guided versus APTT-guided management of intravenous unfractionated heparin in patients requiring a durable ventricular assist device.
    Alfehaid L; Abdallah G; Kothari S; Nguyen K; Alsuhebany N; Badreldin HA; Sabe M
    Int J Cardiol; 2024 Dec; 417():132495. PubMed ID: 39216749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
    Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
    J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Antifactor Xa and Activated Partial Thromboplastin Time Monitoring for Heparin Dosing in Vascular Surgery Patients: A Single-Center Retrospective Study.
    Rizk E; Wilson AD; Murillo MU; Putney DR
    Ther Drug Monit; 2018 Feb; 40(1):151-155. PubMed ID: 29120972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery.
    Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM
    J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.
    Trucco M; Lehmann CU; Mollenkopf N; Streiff MB; Takemoto CM
    J Thromb Haemost; 2015 May; 13(5):788-94. PubMed ID: 25740425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms.
    Whitman-Purves E; Coons JC; Miller T; DiNella JV; Althouse A; Schmidhofer M; Smith RE
    Clin Appl Thromb Hemost; 2018 Mar; 24(2):310-316. PubMed ID: 29212374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children.
    Kuhle S; Eulmesekian P; Kavanagh B; Massicotte P; Vegh P; Lau A; Mitchell LG
    Haematologica; 2007 Apr; 92(4):554-7. PubMed ID: 17488668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review.
    Smith AR; Dager WE; Gulseth MP
    Am J Health Syst Pharm; 2020 Aug; 77(Suppl 3):S59-S65. PubMed ID: 32719867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
    Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
    Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
    Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
    JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.